Genprex TUSC2 Research to Be Presented at GSA 2026
Genprex said research on TUSC2 gene therapy and cellular resilience will be presented at the GSA 2026 Annual Scientific Meeting.
Related stories
APi Group Reports Record Q3 Revenue, Raises 2026 Outlook
APi Group reported third-quarter 2026 net revenues of $2.554 billion, up 22.5% year over year, and net income of $114 million. Adjusted EBITDA rose 24.6% to $350 million; adjusted
M impact | EQUITY | Oct 29, 2026, 12:35 PM UTC
Guaranty Trust Holding Reports Third-Quarter Results
M impact | EQUITY | Oct 29, 2026, 12:25 PM UTC
Harley-Davidson Shares Slip After Q3 Results as Shipments Fall
Harley-Davidson shares slipped after its third-quarter results, which showed shipments fell.
M impact | EQUITY | Oct 29, 2026, 12:24 PM UTC
China Longyuan Power Q3 Net Profit Falls 57.84% Year Over Year
M impact | EQUITY | Oct 29, 2026, 12:24 PM UTC
Ameriprise Financial Posts Q3 Revenue of $5.19B
Ameriprise Financial reported Q3 total revenue of $5.19 billion, versus FactSet estimates of $5.10 billion.
M impact | EQUITY | Oct 29, 2026, 12:23 PM UTC
Yunda Holding Group Q3 Net Profit Rises 28.28% Year Over Year
M impact | EQUITY | Oct 29, 2026, 12:23 PM UTC